The goal of this study is to evaluate the efficacy of the LC-Plasma in preventing upper respiratory tract infections (URTIs) in healthy volunteers. Researchers will compare LC-Plasma to placebo to see if LC-Plasma prevents URTIs. Participants will take a tablet containing LC-Plasma or placebo daily for 24 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
637
RDC Clinical
Brisbane, Queensland, Australia
Cumulative incidence number of URTIs
Cumulative incidence number of Upper Respiratory Tract Infections (URTIs)
Time frame: Day 1 to 24 weeks
Cumulative number of infected participants
Cumulative number of infected participants
Time frame: Day 1 to week 24
Cumulative number of days that participant recorded symptom positive to WURSS-24 system
Cumulative number of days that participant recorded symptom positive to WURSS-24 (Wisconsin Upper Respiratory Symptom Survey) scoring system during intervention period.
Time frame: Day 1 to week 24
Cumulative scores of each parameter in WURSS-24 scoring system, as well as the total sum of all parameters for each participant.
Cumulative scores of each parameter in WURSS-24 scoring system during the intervention period, as well as the total sum of all parameters for each participant.
Time frame: Day 1 to week 24
Length of URTI symptomatic days per one URTI episode.
Length of Upper Respiratory Tract Infection (URTI) symptomatic days per one URTI episode.
Time frame: Day 1 to week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.